Adenomyosis and Endometrial Cancer: Literature Review.

Gynecol Obstet Invest

Department of Gynaecology, Obstetrics and Urology, Sapienza, University of Rome, Rome, Italy.

Published: October 2018

To confirm the origin of cancer found in both the endometrium and the myometrium is difficult. Cancer may spread from the endometrium into adenomyotic foci or vice versa. Also, premalignant changes may arise at either or both sites. Investigating disease origin enhances our understanding of pathophysiology and prognosis. Additional critical questions are whether women with adenomyosis have a higher risk of endometrial cancer; whether the invasive properties and prognosis of cancer in adenomyosis differ from those arising in the eutopic endometrium and whether the ectopic glandular tissue in adenomyosis becomes altered in the presence of eutopic endometrial cancer. A final question is whether cancer arising within adenomyosis carries a worse prognosis because of its location within the myometrium and the possibility that the presence of adenomyosis facilitates invasion of cancer arising in the eutopic endometrium. The present review explores currently available literature in an attempt to answer these questions and to examine clinical presentations, diagnostic criteria, pathogenesis and prognosis.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000487320DOI Listing

Publication Analysis

Top Keywords

endometrial cancer
12
cancer
8
arising eutopic
8
eutopic endometrium
8
cancer arising
8
adenomyosis
6
adenomyosis endometrial
4
cancer literature
4
literature review
4
review confirm
4

Similar Publications

Clear cell adenocarcinoma of the cervix (CCAC) is a rare subtype of cervical adenocarcinoma. It has been linked to intrauterine exposure to diethylstilbestrol (DES) but can happen in non-DES-exposed patients, albeit less commonly. Presentation is largely vaginal bleeding, emphasizing the importance of considering CCAC in the differential of abnormal vaginal bleeding despite the tumor's rarity.

View Article and Find Full Text PDF

Background: Understanding the risk factors for early recurrence is crucial for improving endometrial cancer (EC) patient outcomes.

Methods: We conducted a retrospective analysis of clinicopathological data from 473 patients diagnosed with EC at the First Affiliated Hospital of Chongqing Medical University between October 2013 and May 2019. We evaluated factors influencing early recurrence(defined as occurring within 12 months after treatment) based on 2023 International Federation of Gynecology and Obstetrics (FIGO) staging system.

View Article and Find Full Text PDF

Context: Breast cancer poses significant challenges due to its high incidence and prevalence, necessitating heightened attention. Understanding how patients prioritize different treatment options based on various attributes can assist healthcare decision-makers in maximizing patient utility. The discrete choice experiment, a conjoint method, facilitates preference elicitation by presenting different attributes and choices.

View Article and Find Full Text PDF

Background: Uterine Corpus Endometrial Carcinoma (UCEC) is a prevalent gynecologic malignancy with complex molecular underpinnings. This study identifies key woundhealing genes involved in UCEC and elucidates their roles through a comprehensive analysis.

Methods: In silico and in vitro experiments.

View Article and Find Full Text PDF

Introduction: Incidence of endometrial cancer (EC) in Hispanic/Latina (H/L) women are higher compared to other race/ethnicities in the United States. EC is the third most common cancer and the fourth cause of cancer-related deaths in Puerto Rican women, yet demographic and clinical information is limited. High rates of EC risk factors such as obesity, diabetes mellitus type 2 (DM2) and hypertension (HTN) have been documented in the Puerto Rican population.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!